Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach

Purpose: Advances in targeted lung cancer therapy now demand accurate classification of non–small cell lung cancer (NSCLC). MicroRNAs (miRNA) are recently discovered short, noncoding genes that play essential roles in tissue differentiation during normal development and tumorigenesis. For example, hsa-miR-205 is a miRNA that is highly expressed in lung squamous cell carcinomas (SqCC) but not in lung adenocarcinomas. The differential expression of miRNAs could be exploited to distinguish these tumor types. Experimental Design: One hundred and two resected NSCLCs were classified as SqCC or adenocarcinoma based on their histologic features and immunohistochemical profiles. Corresponding preoperative biopsies/aspirates that had been originally diagnosed as poorly differentiated NSCLCs were available for 21 cases. A quantitative reverse transcription-PCR diagnostic assay that measures the expression level of hsa-miR-205 was used to classify the carcinomas as SqCC or adenocarcinoma based solely on expression levels. The two sets of diagnoses were compared. Results: Using standard pathologic methods of classification (i.e., microscopy and immunohistochemistry), 52 resected lung carcinomas were classified as SqCCs and 50 as adenocarcinomas. There was 100% concordance between the diagnoses established by conventional and miRNA-based methods. MiRNA profiling also correctly classified 20 of the 21 preoperative biopsy specimens. Conclusions: MiRNA profiling is a highly reliable strategy for classifying NSCLCs. Indeed, classification is consistently accurate even in small biopsies/aspirates of poorly differentiated tumors. Confirmation of its reliability across the full range of tumor grades and specimen types represents an important step toward broad application. Clin Cancer Res; 16(2); 610–9

[1]  A R Feinstein,et al.  Observer Variability in the Histopathologic Diagnosis of Lung Cancer1, 2 , 2015 .

[2]  C. Bingle Thyroid transcription factor-1. , 1997, The international journal of biochemistry & cell biology.

[3]  J. Whitsett,et al.  Nuclear localization domain of thyroid transcription factor-1 in respiratory epithelial cells. , 1997, The Biochemical journal.

[4]  Anthony Rhodes,et al.  Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. , 2002, American journal of clinical pathology.

[5]  D. Burstein,et al.  P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.

[6]  S. Lau,et al.  Thyroid Transcription Factor-1: A Review , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  G. Elmberger,et al.  Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma , 2003, British Journal of Cancer.

[8]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[9]  A. Gown,et al.  p63 Expression in Lung Carcinoma: A Tissue Microarray Study of 408 Cases , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  J. Johansson,et al.  Processing of Pulmonary Surfactant Protein B by Napsin and Cathepsin H* , 2004, Journal of Biological Chemistry.

[11]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. A. Robinson,et al.  Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. , 2004, Journal of the National Cancer Institute.

[13]  Yuriy Gusev,et al.  Real-time expression profiling of microRNA precursors in human cancer cell lines , 2005, Nucleic acids research.

[14]  Isaac Bentwich Prediction and validation of microRNAs and their targets , 2005, FEBS letters.

[15]  T. Stephenson,et al.  HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques , 2005, Journal of Clinical Pathology.

[16]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[17]  R M Levenson,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.

[18]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[19]  D. Zander,et al.  TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material , 2006, Modern Pathology.

[20]  R. Lavker,et al.  MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. , 2006, Molecular vision.

[21]  K. Jöckel,et al.  Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. , 2006, Lung cancer.

[22]  J. Soria,et al.  Targeted therapies in lung cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  H. Kato,et al.  Napsin A (TA02) is a useful alternative to thyroid transcription factor‐1 (TTF‐1) for the identification of pulmonary adenocarcinoma cells in pleural effusions , 2007, Diagnostic cytopathology.

[24]  Richard Pazdur,et al.  FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. , 2007, The oncologist.

[25]  A. Kargı,et al.  The Diagnostic Value of TTF-1, CK 5/6, and p63 Immunostaining in Classification of Lung Carcinomas , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[26]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[27]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[28]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[29]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[30]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[31]  H. Asamura,et al.  Immunohistochemical expression of TTF‐1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity , 2007, Pathology international.

[32]  A. Burny,et al.  Evolution of microRNA expression during human bronchial squamous carcinogenesis , 2008, European Respiratory Journal.

[33]  Gideon Rechavi,et al.  Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Bo Jian,et al.  Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens , 2009, Diagnostic cytopathology.

[35]  C. Gomez-Fernandez,et al.  P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples , 2009, Cancer.